Member Info for liquid1

Hypothetically, if there were 370m shares in issue, the price would be 10p, and folks would be talking about a possibility for so getting to 100p.

So practically, a talk of £5 is only 50p, and £10 is only a 100p.

Possibility of + £5 on good results seems seriously possible.

Let’s see what tomorrow brings.

Remember NYCT on their test with double our shares went from 17p to 1200p over a couple of months.

We need ground breaking results.

Positive results leak?

Roll on Monday.

News must therefore be Monday!

If positive this will seriously motor!

Market Cap. 107.26M

At 7:30 premarket when the opening price was 10p, some mm’s mate bought 500,000 shares at 10p and therefore we opened at 20p, 100% higher! FFS!

So mm’s are walking sp back f down. They have learnt from KNB to start way high, and bring down by the balls!

To effining clever these mm’s!

AIMO

After weekend press expect sp to double

Demand is bloody high!

IG asking for 29p????

Going wrong way

I’m out

Gone NT to buy

On Thursday last week RNS came at 1:00pm, maybe another is on its way this afternoon!

18th February
1:00 pm
RNS
Factsheet Remote Monitored Sys (RMS) Update on commissioning and board changes

https://twitter.com/coinminer2049er/status/1364889753804558339?s=21

Prof Carl Smythe, who leads the University of Sheffield team, commented, "We are very pleased with the rapid performance of our sample capture device. Together with the analytical sensitivity and speed of the optical system, we are on track to deliver a robust test that will support the level of infection control required globally."

Was 140p only 2 days ago

“I don’t think people realise just how powerful is the technology we have available.”

Can only be blue days ahead

Great reply from Prof Carl Smythe. The kind of test BRH is involved in is a quick and accurate test. Just the kind that is needed in the coming weeks/months. Testing is not going to go away for some time if we have to live with the virus still able to spread around!!

https://twitter.com/kv07742012/status/1364129861720285184?s=21

07:51:05 30.00 6,800 2,040

Hope sp test high of 49p last week

Avihu Tamir, Kanabo's CEO commented:

"We believe this new product will be revolutionary for medical cannabis patients who need immediate relief of pain, and will replace the smoking of cannabis flowers as a medical delivery method, which is one of Kanabo's main targets."

Dean Friday, LYPHE's CEO commented:

"We have seen the headlines, and we have witnessed the negative impact of opioids. Pain is not going to go away, so a more natural and caring approach to treating it must find centre stage. Thanks to our partnership with Kanabo we now have a metered dose product that can treat patients across the U.K. that suffer from chronic pain.

GATEWAY TO
THE EUROPEAN
CANNABIS MARKET.
End-to-end solution management for the import
and distribution of medical cannabis.

https://astral.health/

23 February 2021

Kanabo Group Plc

("Kanabo" or the "Company")

UK Medicinal Cannabis Distribution Agreement

Kanabo Group Plc (LSE:KNB), the medicinal cannabis company that recently debuted on the London Stock Exchange, is delighted to announce it has signed its first UK medicinal cannabis distribution framework agreement with Astral Health Limited ("Astral Health"). Astral Health is fully owned by LYPHE Group, which is part of Drug Science's Project Twenty21.

LYPHE Group has built a patient-access ecosystem that provides clinics, dispensing, import infrastructure and educational services to patients, doctors and the industry in the UK. It is one of the main players in the embryonic but fast-developing medicinal cannabis market in the UK.

Through this new framework agreement, it is intended that Kanabo's VapePod medicinal cannabis formula, under brand NOIDECS will be made available to Project Twenty21 patients. Project Twenty21 provides eligible patients with affordable medical cannabis treatment, monitored by Drug Science. The project aims to create the UK's largest body of evidence for the effectiveness and tolerability of medical cannabis.

The initial formula which Astral Health will distribute under the name NOIDECS 400T, is based on the Israeli medical cannabis pharmacopoeia as a recommended ratio for pain management. Kanabo and Astral Health will work closely together to make the products available to patients over the next 3-6 months.

Under the framework agreement, Astral Health acquires rights to sell the Company's VapePod and certain medicinal cannabis oils in the United Kingdom.

Avihu Tamir, Kanabo's CEO commented:

"We believe this new product will be revolutionary for medical cannabis patients who need immediate relief of pain, and will replace the smoking of cannabis flowers as a medical delivery method, which is one of Kanabo's main targets."

Dean Friday, LYPHE's CEO commented:

"We have seen the headlines, and we have witnessed the negative impact of opioids. Pain is not going to go away, so a more natural and caring approach to treating it must find centre stage. Thanks to our partnership with Kanabo we now have a metered dose product that can treat patients across the U.K. that suffer from chronic pain."